The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program in Practice: Does It Really Inform Patients and Limit Risk?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2012-05, Vol.59 (5), p.604-606
Hauptverfasser:	Cohen, Robert A., MD, MSc, Brown, Robert S., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Chronic Disease Epoetin Alfa Erythropoietin - adverse effects Heart Failure - epidemiology Hematinics - adverse effects Humans Kidney Diseases - therapy Nephrology Patient Education as Topic - methods Physician-Patient Relations Recombinant Proteins - adverse effects Renal Dialysis Risk Assessment - methods Risk Factors Risk Management Stroke - epidemiology United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!